What we are studying
The first purpose of the study is to determine whether a single dose of Thymoglobulin is as safe as the standard divided-dose plan. Thymoglobulin is a medication intended to prevent the body from rejecting the transplanted kidney. The standard method is to administer multiple doses of Thymoglobulin over a period of several days, with the first dose being administered in the operating room. In the single dose arm, the entire Thymoglobulin dose will be administered in the operating room and completed within 24-28 hours. The total amount of Thymoglobulin given will be the same in either dosing plan. The second purpose of the study is to determine whether these two dosing plans are equally effective at preventing rejection and obtaining the best possible function from the transplanted kidney.